NEW YORK (GenomeWeb News) – Transgenomic said today that it has expanded a national contractual agreement with the Blue Cross and Blue Shield Association.

The Omaha, Neb.-based molecular diagnostics and pharmacogenomics services firm said in a filing with the US Securities and Exchange Commission that the new agreement has a term of five years. Under the contract, Blue Plans affiliates have access to "competitive pricing" for Transgenomic's tests and services.

The firm didn't provide any additional details of the contract.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.